[{"address1": "Wallstra\u00dfe 16", "city": "Berlin", "zip": "10179", "country": "Germany", "phone": "49 89 2153 9035", "website": "https://atai.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic in Phase 2a trial for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists in preclinical studies for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.", "fullTimeEmployees": 54, "companyOfficers": [{"maxAge": 1, "name": "Mr. Christian  Angermayer", "age": 46, "title": "Co-Founder & Chairman of the Supervisory Board", "yearBorn": 1978, "fiscalYear": 2024, "totalPay": 73104, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Srinivas G. Rao M.D., Ph.D.", "age": 55, "title": "Co-Founder, CEO & Executive Director", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 834460, "exercisedValue": 0, "unexercisedValue": 39375}, {"maxAge": 1, "name": "Ms. Anne  Johnson", "age": 55, "title": "Chief Financial Officer", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 574815, "exercisedValue": 0, "unexercisedValue": 32812}, {"maxAge": 1, "name": "Dr. Gerd G. Kochendoerfer Ph.D.", "age": 56, "title": "Chief Operating Officer", "yearBorn": 1968, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Glenn  Short Ph.D.", "age": 54, "title": "Chief Scientific Officer", "yearBorn": 1970, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  Barrett J.D.", "age": 43, "title": "General Counsel & Corporate Secretary", "yearBorn": 1981, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kevin  Craig M.D.", "age": 51, "title": "Chief Medical Officer", "yearBorn": 1973, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 4.56, "open": 4.6, "dayLow": 4.415, "dayHigh": 4.65, "regularMarketPreviousClose": 4.56, "regularMarketOpen": 4.6, "regularMarketDayLow": 4.415, "regularMarketDayHigh": 4.65, "payoutRatio": 0.0, "beta": 1.562, "forwardPE": -6.720588, "volume": 3118219, "regularMarketVolume": 3118219, "averageVolume": 5999130, "averageVolume10days": 5804700, "averageDailyVolume10Day": 5804700, "bid": 3.3, "ask": 4.57, "bidSize": 2, "askSize": 1, "marketCap": 979524672, "fiftyTwoWeekLow": 1.03, "fiftyTwoWeekHigh": 5.34, "priceToSalesTrailing12Months": 424.2203, "fiftyDayAverage": 3.6488, "twoHundredDayAverage": 2.1682, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 895486144, "profitMargins": 0.0, "floatShares": 116368566, "sharesOutstanding": 214338000, "sharesShort": 15325335, "sharesShortPriorMonth": 16175083, "sharesShortPreviousMonthDate": 1752537600, "dateShortInterest": 1755216000, "sharesPercentSharesOut": 0.0715, "heldPercentInsiders": 0.07699, "heldPercentInstitutions": 0.39806, "shortRatio": 2.21, "shortPercentOfFloat": 0.0915, "impliedSharesOutstanding": 214338000, "bookValue": 0.677, "priceToBook": 6.7503695, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -119404000, "trailingEps": -0.69, "forwardEps": -0.68, "enterpriseToRevenue": 387.824, "enterpriseToEbitda": -9.441, "52WeekChange": 2.685484, "SandP52WeekChange": 0.18469036, "quoteType": "EQUITY", "currentPrice": 4.57, "targetHighPrice": 16.0, "targetLowPrice": 7.0, "targetMeanPrice": 11.28571, "targetMedianPrice": 11.0, "recommendationKey": "none", "numberOfAnalystOpinions": 7, "totalCash": 95943000, "totalCashPerShare": 0.448, "ebitda": -94849000, "totalDebt": 11716000, "quickRatio": 3.807, "currentRatio": 4.019, "totalRevenue": 2309000, "debtToEquity": 8.14, "revenuePerShare": 0.013, "returnOnAssets": -0.29507, "returnOnEquity": -0.76499003, "grossProfits": 2309000, "freeCashflow": -17686500, "operatingCashflow": -75571000, "revenueGrowth": 1.634, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -35.15021, "financialCurrency": "USD", "symbol": "ATAI", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "messageBoardId": "finmb_710359021", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "corporateActions": [], "postMarketTime": 1757116791, "regularMarketTime": 1757102402, "shortName": "ATAI Life Sciences N.V.", "longName": "Atai Life Sciences N.V.", "regularMarketChangePercent": 0.219303, "regularMarketPrice": 4.57, "epsTrailingTwelveMonths": -0.69, "epsForward": -0.68, "epsCurrentYear": -0.50333, "priceEpsCurrentYear": -9.079531, "fiftyDayAverageChange": 0.9212003, "fiftyDayAverageChangePercent": 0.25246665, "twoHundredDayAverageChange": 2.4018002, "twoHundredDayAverageChangePercent": 1.1077392, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-06-18", "cryptoTradeable": false, "exchange": "NGM", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1624023000000, "postMarketChangePercent": 0.0, "postMarketPrice": 4.57, "postMarketChange": 0.0, "regularMarketChange": 0.0100002, "regularMarketDayRange": "4.415 - 4.65", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 5999130, "fiftyTwoWeekLowChange": 3.5400002, "fiftyTwoWeekLowChangePercent": 3.4368935, "fiftyTwoWeekRange": "1.03 - 5.34", "fiftyTwoWeekHighChange": -0.77, "fiftyTwoWeekHighChangePercent": -0.14419475, "fiftyTwoWeekChangePercent": 268.5484, "earningsTimestamp": 1755057600, "earningsTimestampStart": 1763037000, "earningsTimestampEnd": 1763037000, "isEarningsDateEstimate": true, "marketState": "CLOSED", "displayName": "Atai Life Sciences", "trailingPegRatio": null, "__fetch_time": "2025-09-06"}]